Last edition
News about "NK Cell Therapy"
Ichnos Glenmark Innovation Unveils Novel Multispecific Antibody Candidate for Solid Tumour Treatment
Ichnos Glenmark Innovation has introduced ISB 2301, a next-generation multispecific antibody designed to activate immune cells and target solid tumours through a multi-mechanism approach aimed at improving cancer treatment outcomes.
NK Cell Therapy | 22/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members